Kinder Morgan Files Regulation FD Disclosure with SEC
Quick Brief
Kinder Morgan, Inc. has submitted a Form 8-K filing to the U.S. Securities and Exchange Commission. The regulatory filing specifically addresses Item 7.01 concerning Regulation FD Disclosures. The document totals 228 kilobytes in size.
What Happened?
Kinder Morgan, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission containing a Regulation FD Disclosure under Item 7.01.
Why It Matters
Form 8-K filings under Regulation FD Disclosure are used by publicly traded companies to publicly disclose material, non-public information to the market, ensuring fair access for investors.
Key Facts
- Filer: Kinder Morgan, Inc.
- Filing Type: Form 8-K
- SEC Central Index Key (CIK): 0001506307
- Filing Content: Item 7.01 Regulation FD Disclosure
- Filing Size: 228 KB
Compiled from 1 outlet
Related Stories
Malabar Milma Approves ₹1.72 Crore Subsidy for Cattle Feed in Keralam
Malabar Milma has sanctioned a ₹1.72 crore subsidy aimed at supporting dairy farmers in Keralam. Through this financial backing, cattle feed will be accessible at reduced prices during September 2026. The initiative is being implemented across all primary dairy cooperative societies within the Malabar region.
NHAI Terminates Arakkonam-Kancheepuram Builder Contract for Bengaluru-Chennai Expressway
The National Highways Authority of India (NHAI) has officially canceled the construction contract for the Arakkonam-Kancheepuram section of the Bengaluru-Chennai Expressway. To finish the remaining construction, new tenders have been issued under the engineering, procurement, and construction (EPC) mode.
FDA Revokes Drug Sale Licences for Cipla's Pune Facility Over Storage Violations
The food and drug administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences' carry and forwarding unit in Pune. Regulators discovered that pharmaceutical products were being kept directly on the floor. Additionally, authorities identified significant deficiencies in the protocols used for managing expired medicines.
RPG Life Sciences to Acquire Raghava Life Sciences' API Business for ₹135 Crore
RPG Life Sciences is moving to expand its operations by acquiring the active pharmaceutical ingredient (API) and intermediates business of Raghava Life Sciences. The transaction is valued at ₹135 crore. The purchase strengthens RPG Life Sciences' portfolio in the pharmaceutical sector.